Hemogenyx Pharma Stock Price, News & Analysis

Hemogenyx Pharmaceuticals plc has successfully completed its second and final Process Development run for HEMO-CAR-T cell manufacturing in cGMP-compliant facilities. This advancement is a crucial step towards submitting the Investigational New Drug application to the FDA for initiating Phase I clinical trials of HEMO-CAR-T. The company is now preparing for engineering runs as part of its Process Qualification phase. Hemogenyx focuses on developing innovative therapies for serious blood diseases and aims to enhance patient access to life-saving bone marrow transplants.

Hemogenyx Pharmaceuticals has released its interim results for the six months ending June 30, 2022. The company reported a loss of £1,300,653, a decrease from the £3,632,338 loss in 2021, with cash reserves of £5,799,495. Key advancements include the preparation to file an Investigational New Drug (IND) application for HEMO-CAR-T, bolstered scientific teams, and the establishment of a new facility in Manhattanville, New York. The company continues to explore the development of CDX antibodies and Chimeric Bait Receptor platforms.

Hemogenyx Pharmaceuticals will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York City from September 12-14, 2022. CEO Dr. Vladislav Sandler will discuss the company's progress in developing therapies for blood diseases. The conference will feature corporate presentations and investor meetings, accessible through a webcast. This event aims to boost Hemogenyx's visibility and establish its role in treating severe blood and autoimmune diseases, underlining the potential impact of their bone marrow transplantation technologies.

Hemogenyx Pharmaceuticals announces the appointment of Stuart Tinch as Director of Quality, enhancing their commitment to Good Manufacturing Practice (GMP) standards. Tinch, with over seven years of experience, will focus on implementing quality systems for the company’s lead therapy, HEMO-CAR-T, currently being prepared for clinical trials. His previous role at Expression Therapeutics involved establishing GMP facilities, which aligns with Hemogenyx's goals of ensuring high-quality standards for its product candidates.

Hemogenyx Pharmaceuticals announced the grant of a significant patent by the China National Intellectual Property Administration for its bi-specific antibody technology, enhancing its intellectual property portfolio. The granted patent (No. 201780034711.2) pertains to an innovative method to eliminate hematopoietic stem cells for patients undergoing bone marrow transplantation. This breakthrough could potentially reduce reliance on toxic conditioning treatments, significantly impacting blood cancer therapy, including acute myeloid leukemia. The original application dates back to April 2016, with US rights granted in 2021.

Hemogenyx Pharmaceuticals has opened a new custom-engineered laboratory in the Mink Building, West Harlem, expanding its cell therapy capabilities. The facility features approx. 10,000 sq ft including two clean rooms for manufacturing its HEMO-CAR-T cell therapy aimed at treating acute myeloid leukemia. This move supports the company's growth in a prominent life sciences cluster near Columbia University. Hemogenyx, previously at SUNY Downstate, aims to simplify the commercialization of its product candidates.

Hemogenyx Pharmaceuticals announced that a recording of the investor webinar held on July 6, 2022, featuring CEO Dr. Vladislav Sandler, is now accessible on their YouTube channel. The company focuses on developing innovative treatments for blood and autoimmune diseases, leveraging technology to improve bone marrow transplantation outcomes. Hemogenyx emphasizes that their advancements could significantly benefit patients with conditions like leukemia, lymphoma, and severe autoimmune disorders.

Hemogenyx Pharmaceuticals plc has officially changed its registered office address to 6th Floor, 60 Gracechurch Street, London, EC3V 0HR, effective immediately. This relocation aims to enhance operational efficiency and accessibility. Hemogenyx continues to focus on developing innovative treatments for blood diseases, with its corporate governance structure remaining intact. The announcement reflects the company’s commitment to maintaining a professional presence in a key financial district in London.

Hemogenyx Pharmaceuticals has reported that all resolutions were passed at its Annual General Meeting on June 30, 2022. Key resolutions included the adoption of the 2021 Annual Report, approval of the Directors' Remuneration Policy, and reappointment of the Company’s auditor. Notably, the resolution for the Directors' Remuneration Policy had 84.7% votes in favor, while the Employee Incentive Plan garnered 97.9% approval. The total issued share capital as of June 28, 2022, was 979,749,321 shares. Full voting details are available via the National Storage Mechanism.